SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Hesselius Patrik)
 

Search: WFRF:(Hesselius Patrik) > Serological and imm...

  • Bolander, ÅsaUppsala universitet,Enheten för onkologi (author)

Serological and immunohistochemical analysis of S100 and derivatives as markers for prognosis of newly operated malignant melanoma patients

  • Article/chapterEnglish2008

Publisher, publication year, extent ...

  • 2008
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-97932
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-97932URI
  • https://doi.org/10.1097/CMR.0b013e328315c690DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The incidence of cutaneous malignant melanoma is rising, and tumour markers are attracting attention as a possible alternative to clinical examination in the follow-up situation. S100 is the preferred marker for malignant melanoma, and correlation between serum S100 and disease relapse and survival has been reported. S100 tests previously used in clinical studies were specified poorly regarding reactivity with S100A1B and S100BB. In this study, a newly designed S100 assay (designed to measure exclusively S100A1B and S100BB) and two newly developed serological assays, S100A1B, and S100BB, were investigated postoperatively in patients undergoing radical surgery for cutaneous malignant melanoma. Additionally, immunohistochemical analysis of S100A4 was performed on the primary malignant melanoma using tissue microarrays. The primary aim of the study was to investigate whether any of these assays, either singly or in combination, can contribute additional information concerning increased risk of relapse and death because of malignant melanoma. In total, 98 patients (54 males, 44 females) with malignant melanoma were included in the study. As a continuous variable, S100BB (P=0.016) was associated statistically with increased risk of relapse; this was not the case for increased values of either S100 (P=0.11) or S100A1B (P=0.92). The Kaplan-Meier overall survival as well as disease specific survival curve for the S100 serum level demonstrated a statistically significant association with better survival if the patient had a S100 level

Subject headings and genre

  • immunohistochemistry
  • malignant melanoma
  • prognosis
  • S100
  • S100A1B
  • S100A4
  • S100BB
  • serum marker
  • survival
  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Agnarsdóttir, MargrétUppsala universitet,Institutionen för genetik och patologi(Swepub:uu)marag973 (author)
  • Wagenius, GunnarUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)gunnwage (author)
  • Strömberg, SaraUppsala universitet,Institutionen för genetik och patologi (author)
  • Pontén, FredrikUppsala universitet,Institutionen för genetik och patologi(Swepub:uu)fredpont (author)
  • Ekman, Simon (author)
  • Brattström, Daniel (author)
  • Larsson, AndersUppsala universitet,Klinisk kemi,Biologisk struktur och funktion(Swepub:uu)andla606 (author)
  • Einarsson, Roland (author)
  • Ullenhag, GustavUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)gustulle (author)
  • Hesselius, PatrikUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)patrhess (author)
  • Bergqvist, MichaelUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi(Swepub:uu)michberg (author)
  • Uppsala universitetEnheten för onkologi (creator_code:org_t)

Related titles

  • In:Melanoma research18:6, s. 412-4190960-89311473-5636

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view